MD

Melissa Dumble

GL Glaxosmithkline: 4 patents #75 of 646Top 15%
PP Pmv Pharmaceuticals: 2 patents #6 of 8Top 75%
NA Novartis Ag: 1 patents #2,882 of 5,128Top 60%
PT Ptc Therapeutics: 1 patents #120 of 160Top 75%
Overall (All Time): #607,384 of 4,157,543Top 15%
8
Patents All Time

Issued Patents All Time

Patent #TitleCo-InventorsDate
12419880 Companion diagnostic tool for mutant p53 reactivating compounds 2025-09-23
12023335 Method for treating pancreatic cancer Marla L. Weetall, Liangxian Cao, Thomas Davis, Jaime A. Eberle-Singh, Kenneth P. Olive 2024-07-02
11938124 Combination therapy for treatment of cancer Arnold J. Levine 2024-03-26
9402846 Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer Tona Gilmer, Rakesh Kumar, Sylvie Laquerre, Peter F. Lebowitz, Shannon Renae Morris 2016-08-02
8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Rakesh Kumar, Sylvie Laquerre, Peter F. Lebowitz 2015-02-10
8835450 Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer Tona Gilmer, Rakesh Kumar, Peter F. Lebowitz, Shannon Renae Morris, Sylvie Laquerre 2014-09-16
8796298 Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer Tona Gilmer, Rakesh Kumar, Peter F. Lebowitz, Shannon Renae Morris, Sylvie Laquerre 2014-08-05
8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors Rakesh Kumar, Sylvie Laquerre, Peter F. Lebowitz 2014-04-22